AstraZeneca Nordic Baltic
This sponsor has funded 4 studies across 1 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 6161 | Finalised | A retrospective cohort study to investigate the initiation and persistence of dual antiplatelet treatment after acute coronary syndrome in a Finnish... | Yes | Yes |
| 8202 | Finalised | A retrospective nationwide cohort study to investigate the treatment of type 2 diabetic patients in Finland - DAHLIA | Yes | Yes |
| 8205 | Finalised | Risk of subsequent cardiovascular events in patients discharged after myocardial infarction - Perseus (PERSEUS) | Yes | No |
| 21945 | Planned | Patient characteristics and cardiovascular and mortality outcomes in patients with type 2 diabetes mellitus initiating treatment with sodium-glucose... | Yes | No |
PAS by Risk Management Plan (RMP) requirement
AstraZeneca Nordic Baltic
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
AstraZeneca Nordic Baltic
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
AstraZeneca Nordic Baltic
1 Study countries specified are the following:
- Finland